Related Experiment Video
Updated: Aug 5, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib
Teresa Grieco1, Martina Caviglia1, Giuseppina Cusano2
1Dermatology Unit, Department of Clinical Internal Anesthesiological and Cardiovascular Sciences, "Sapienza" University of Rome, 00161 Rome, Italy.
Medicina (Kaunas, Lithuania)
|March 29, 2023
Summary
Upadacitinib effectively treated a patient with both ulcerative colitis and atopic dermatitis. A low dose achieved remission in both Th1 and Th2 immune-mediated diseases without serious side effects.
Area of Science:
- Immunology
- Dermatology
- Gastroenterology
Background:
- Janus Kinase (JAK) inhibitors are used for immune-related diseases and atopic dermatitis.
- They target the JAK intracellular cascade, impacting Th1 and Th2 responses.
Observation:
- A 36-year-old male had coexisting ulcerative colitis (Th1-mediated) and atopic dermatitis (Th2-mediated).
- Treatment with upadacitinib was administered and monitored for 8 months.
Findings:
- Complete and sustained clinical remission of both ulcerative colitis and atopic dermatitis was achieved.
- A low dose of 15 mg upadacitinib was effective, below the typical 45 mg for ulcerative colitis.
- No serious adverse events were reported during the treatment period.
Implications:
- Upadacitinib shows potential as a management strategy for patients with overlapping Th1 and Th2 immune-mediated diseases.
- This finding suggests a targeted approach for complex inflammatory conditions.
- Further research may explore optimal dosing for combined conditions.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
191
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
191
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
168
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
168
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
213
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
213
01:29Inflammatory Bowel Disease IV: Pharmacological Management
165
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
165
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
188
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
188
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
248
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
248